| __timestamp | Catalyst Pharmaceuticals, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4473654 | 35942000 |
| Thursday, January 1, 2015 | 8597010 | 40028000 |
| Friday, January 1, 2016 | 7910260 | 45853000 |
| Sunday, January 1, 2017 | 7304399 | 53816000 |
| Monday, January 1, 2018 | 15875961 | 60804000 |
| Tuesday, January 1, 2019 | 36881187 | 77252000 |
| Wednesday, January 1, 2020 | 44233754 | 45736000 |
| Friday, January 1, 2021 | 49628000 | 50323000 |
| Saturday, January 1, 2022 | 58183000 | 143526000 |
| Sunday, January 1, 2023 | 133710000 | 149182000 |
| Monday, January 1, 2024 | 154335000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, Halozyme consistently outspent Catalyst, with expenses peaking at approximately $149 million in 2023, a 316% increase from 2014. Meanwhile, Catalyst's SG&A expenses surged by nearly 2,889% over the same period, reaching around $134 million in 2023. This dramatic rise highlights Catalyst's aggressive expansion strategy. Despite the higher expenses, both companies have shown resilience and adaptability in a rapidly evolving market. Investors and stakeholders should consider these trends when evaluating the operational efficiency and strategic direction of these biotech firms.
Comparing SG&A Expenses: Eli Lilly and Company vs Halozyme Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: AbbVie Inc. vs Halozyme Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Catalyst Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Intra-Cellular Therapies, Inc. or Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: Dr. Reddy's Laboratories Limited vs Catalyst Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Taro Pharmaceutical Industries Ltd.
Blueprint Medicines Corporation and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Verona Pharma plc or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Vericel Corporation and Catalyst Pharmaceuticals, Inc.